Flag of the European Union EU Clinical Trials Register Help

Clinical trials for c fos

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: c fos. Displaying page 1 of 1.
    EudraCT Number: 2020-001750-22 Sponsor Protocol Number: 20HH5926 Start Date*: 2020-07-09
    Sponsor Name:Joint Research Compliance Office
    Full Title: MATIS: Phase 2/3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia
    Medical condition: COVID-19 pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-004265-12 Sponsor Protocol Number: NBI-921352-FOS2022 Start Date*: 2021-12-21
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with Focal Onset Seizures (FOS)
    Medical condition: Focal Onset Seizures (FOS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10016843 Focal seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) HU (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001433-39 Sponsor Protocol Number: NBI-921352-FOS2021 Start Date*: 2021-09-08
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of NBI-921352 as Adjunctive Therapy in Adult Subjects ...
    Medical condition: Focal Onset Seizures (FOS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10016843 Focal seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001207-37 Sponsor Protocol Number: HUB-IDIBELL-SAFO-4.3.1 Start Date*: 2019-04-26
    Sponsor Name:Miquel Pujol i Rojo ( Servicio de Enfermedades Infecciosas del Hospital Universitari de Bellvitge
    Full Title: Phase IV-III Clinical Trial, randomized, controlled, open and multicentric, with parallel groups, to evaluate the efficacy of Cloxacillin and fosfomycin combination versus Cloxacillin monotherapy i...
    Medical condition: Methicilin-susceptible S.aureus bacteraemia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10058863 Staphylococcus aureus bacteraemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005706-11 Sponsor Protocol Number: Cyst2016_01 Start Date*: 2016-03-14
    Sponsor Name:Vita Green Europa S.A.
    Full Title: Single-site, open, randomized clinical trial to assess the non-inferiority of Cysticlean® versus Fosfomicina in the treatment of cystitis in women in Spain.
    Medical condition: Urinary Tract Infection (UTI)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10011790 Cystitis escherichia PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001448-78 Sponsor Protocol Number: Cyst2018_01 Start Date*: 2018-11-08
    Sponsor Name:Vita Green Europa S.A.
    Full Title: Single-site, open, randomized clinical trial to assess the non-inferiority of Cysticlean® versus Fosfomicina in the treatment of cystitis in women in Spain.
    Medical condition: Urinary Tract Infection (UTI)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011790 Cystitis escherichia PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003792-19 Sponsor Protocol Number: FOS-PROST-001 Start Date*: 2021-03-04
    Sponsor Name:Hospital Universitari Mutua Terrassa
    Full Title: Fosfomycin as an oral alternative treatment for acute bacterial prostatitis due to multi-drug resistant Escherichia coli. Pilot study
    Medical condition: Acute bacterial prostatitis due to multi-drug resistant Escherichia coli
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003605-26 Sponsor Protocol Number: PRO044-CLIN-02 Start Date*: 2014-12-02
    Sponsor Name:Prosensa Therapeutics B.V.
    Full Title: A phase II, open label, extension study to assess the effect of PRO044 in patients with Duchenne muscular dystrophy
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Completed) SE (Prematurely Ended) NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002257-11 Sponsor Protocol Number: C.A.S.T. Start Date*: 2020-12-14
    Sponsor Name:AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO
    Full Title: A phase I study of adoptive immunotherapy with Cytokine-Induced Killer (CIK) cells in relapsed and non-resectable sarcomas after multimodal treatment.
    Medical condition: patients with advanced and non-resectable sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005040-10 Sponsor Protocol Number: PRO045-CLIN-01 Start Date*: 2012-12-03
    Sponsor Name:BioMarin Nederland B.V.
    Full Title: A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple subcutaneous doses of PRO045 in subjects with Duchenne muscular dystrophy
    Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skipping
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: BE (Completed) GB (Completed) IT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005042-35 Sponsor Protocol Number: PRO053-CLIN-01 Start Date*: 2013-08-23
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase I/II, open-label, dose escalating with 48 week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053 (previously known as PRO053)...
    Medical condition: Duchenne muscular dystrophy resulting from a mutation correctable by BMN 053-induced DMD exon 53 skipping
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 16:17:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA